4875), today announced enrollment of the first patient in the NIH-funded Expanded Access Program (EAP) trial to evaluate MN-166 (ibudilast) in patients with Amyotrophic Lateral Sclerosis (ALS).

MediciNova (MNOV) announced enrollment of the first patient in the NIH-funded Expanded Access Program trial to evaluate ... Phase 2/3 COMBAT-ALS trial. The EAP trial, funded by the National ...